Journal of Endocrinological Investigation

, Volume 24, Issue 7, pp 522–528 | Cite as

In vivo and in vitro expression of somatostatin receptors in two human thymomas with similar clinical presentation and different histological features

  • Diego Ferone
  • D. J. Kwekkeboom
  • R. Pivonello
  • A. D. J. J. Bogers
  • A. Colao
  • S. W. J. Lamberts
  • P. M. van Hagen
  • L. J. Hofland
Original Article


[111In-DTPA0]octreotide scintigraphy allows the in vivo visualization of several types of SS receptor (SSR)-expressing tumors. Among these, thymomas have been recently detected. Here we report on 2 patients admitted for myasthenia gravis and radiological evidence of thymic mass. Although these patients had similar clinical presentation, in vivo SSR scintigraphy displayed a difference in the degree of the [111In-DTPA0]octreotide uptake. Considering that both thymic masses had comparable volume, [111In-DTPA0]octreotide level was significantly higher in one of the 2 tumors (tumor/background ratio of 5.7 vs 2.6). The SSR subtype expression pattern was studied in vitro on the surgically resected specimens by ligand binding techniques, quantitative reverse transcriptase polymerase chain reaction (RT-PCR) and immunohistochemistry. According to the recent World Health Organization classification, the 2 tumors were classified A and B2 thymomas respectively. In membrane homogenates, we found a higher number of high affinity [125I-Tyr11]-SS-14 binding sites in the B2 thymomas (23.5±2.5 vs 12.0±0.4 fmol/mg membrane protein; p<0.05). RT-PCR analysis showed sst1, sst2A and sst3 mRNA in the 2 thymoma tissues, whereas SS mRNA was detectable only in the A thymoma. Quantitative evaluation of RT-PCR data showed a comparable expression of the relative amount of sst2A mRNA in both tumors, whereas a significant higher expression of sst3 mRNA in the B2 thymoma. Sst2A immunoreactivity was localized mainly on the endothelium of intratumoral vessels, whereas sst3 was present on either tumoral epithelial cells or normal reactive thymocytes. The expression of sst2A receptors in these tumors is in line with the in vivo visualization by [111In-DTPA0]octreotide, which is considered a sst2-preferring ligand. However, since radioligand uptake was significantly higher in the B2 thymoma, which expressed the largest sst3 mRNA levels, it might be possible that this subtype is involved in determining the tumor visualization during SSR scintigraphy. Apart from the affinity of the radioligand for the receptor, also the efficacy of the internalization of the radioligand-receptor complex might play a role in radioactivity accumulation during in vivo SSR scintigraphy. In fact, although octreotide binds with lower affinity to sst3 receptors, this subtype displayed the highest amount of agonist-dependent receptor internalization compared to the other SSR subtypes. Moreover, sst3 was localized on both tumor cells and reactive thymocytes, and these latter cells are characterized by a very active turnover of membrane molecules. Finally, although more cases need to be evaluated, the lack of detection of SS mRNA in the tumor presenting a more aggressive phenotype (B2 thymoma) might have physiopathological or prognostic significance.


Thymoma somatostatin receptor subtypes somatostatin receptors scintigraphy immunohistochemistry reverse transcriptase polymerase chain reaction 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lamberts S.W.J., Krenning E.P., Reubi J.C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev. 1991, 12: 450–482.PubMedCrossRefGoogle Scholar
  2. 2.
    Kwekkeboom D.J., Krenning E.P., de Jong M. Peptide receptor imaging and therapy. J. Nucl. Med. 2000, 41: 1704–1713.PubMedGoogle Scholar
  3. 3.
    Colao A., Ferone D., Lastoria S., Marzullo P., Cerbone G., Di Sarno A., Longobardi S., Merola B., Salvatore M., Lombardi G. Prediction of efficacy of octreotide therapy in patients with acromegaly. J. Clin. Endocrinol. Metab. 1996, 81: 2356–2362.PubMedGoogle Scholar
  4. 4.
    van Hagen P.M., Krenning E.P., Kwekkeboom D.J., Reubi J.C., Anker-Lugtenburg P.J., Löwenberg B., Lamberts S.W.J. Somatostatin and the immune and haematopoietic system; a review. Eur. J. Clin. Invest. 1994, 24: 91–99.PubMedCrossRefGoogle Scholar
  5. 5.
    Ferone D., van Hagen P.M., Colao A., Lombardi G., Lamberts S.W.J., Hofland L.J. Distribution, role and function of somatostatin receptors in immune cells. In: Lamberts S.W.J. (Ed.), Octreotide: The next decade. BioScientifica Ltd, Bristol, 1999, p. 259.Google Scholar
  6. 6.
    Reubi J.C., Waser B., Horisberger U., Krenning E., Lamberts S.W.J., Gebbers J.-O., Gersbach P., Laissue J.A. In vitro and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue. Blood 1993, 82: 2143–2151.PubMedGoogle Scholar
  7. 7.
    Lastoria S., Vergara E., Palmieri G., Acampa W., Varrella P., Caracò C., Bianco A.R., Muto P., Salvatore M. In vivo detection of malignant thymic masses by [111In-DTPA-D-Phe1]-octreotide scintigraphy. J. Nucl. Med. 1998, 39: 634–639.PubMedGoogle Scholar
  8. 8.
    Lin K., Nguyen R.D., Ettinger D.S., Chin B.B. Somatostatin receptor scintigraphy and somatostatin therapy in the evaluation and treatment of malignant thymoma. Clin. Nucl. Med. 1999, 24: 24–28.PubMedCrossRefGoogle Scholar
  9. 9.
    Ferone D., van Hagen P.M., Kwekkeboom D.J., van Koetsveld P.M., Mooy D.M., Lichtenauer-Kaligis E.G.R., Schönbrunn A., Colao A., Lamberts S.W.J., Hofland L.J. Somatostatin receptors in human thymoma and inhibition of cell proliferation by octreotide in vitro. J. Clin. Endocrinol. Metab. 2000, 85: 1719–1726.PubMedCrossRefGoogle Scholar
  10. 10.
    Palmieri G., Lastoria S., Colao A., Vergara E., Varrella P., Biondi E., Selleri C., Catalano L., Lombardi G., Bianco A.R., Salvatore M. Successful treatment of a patient with thymoma and pure red-cell aplasia with octreotide and prednisone. N. Engl. J. Med. 1997, 336: 263–265.PubMedCrossRefGoogle Scholar
  11. 11.
    Ferone D., van Hagen P.M., van Koetsveld P.M., Zuijderwijk J., Mooy D., Lichtenauer-Kaligis E.G.R., Colao A., Bogers A.D.J.J., Lombardi G., Lamberts S.W.J., Hofland L.J. In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells. Endocrinology 1999, 140: 373–380.PubMedCrossRefGoogle Scholar
  12. 12.
    Müller-Hermelink H.K., Marx A. Pathological aspects of malignant and benign thymic disorders. Ann. Med. 1999, 31 (Suppl. 2): 5–14.PubMedGoogle Scholar
  13. 13.
    Andersson P., Forssell-Aronsson E., Johanson V., Wangberg B., Nilsson O., Fjalling M., Ahlman H. Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide. J. Nucl. Med. 1996, 37: 2002–2006.PubMedGoogle Scholar
  14. 14.
    Hofland L.J., van Koetsveld P.M., Waaijers M., Zuyderwijk J., Breeman W.A., Lamberts S.W. Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide. Endocrinology 1995, 136: 3698–3706.PubMedGoogle Scholar
  15. 15.
    Hukovic N., Panetta R., Kumar U., Patel Y.C. Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. Endocrinology 1996, 137: 4046–4049.PubMedGoogle Scholar
  16. 16.
    Hofland L.J., Lamberts S.W.J. Somatostatin and somatostatin receptors. Diagnostic and therapueutic applications. In: Arnold A. (Ed.), Endocrine neoplasms. Kluwer Academic Publisher, Nowell, 1997, p. 365.CrossRefGoogle Scholar
  17. 17.
    Kolby L., Wängberg B., Ahlman H., Tisell L.-E., Fjälling M., Forssell-Aronsson E., Nilsson O. Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors. World J. Surg. 1998, 22: 679–683.PubMedCrossRefGoogle Scholar
  18. 18.
    Ain K.B., Kimberly D.T., Tofiq S., Venkartarman G. Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J. Clin. Endocrinol. Metab. 1997, 82: 1857–1862.PubMedGoogle Scholar
  19. 19.
    Kwekkeboom D.J., Reubi J.C., Lamberts S.W., Bruining H.A., Mulder A.H., Oei H.Y., Krenning E.P In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 1993, 76: 1413–1417.PubMedGoogle Scholar
  20. 20.
    Hishima T., Fukayama M., Hayashi Y., Fujii T., Arai K., Shiozawa Y., Funata N., Koike M. Neuroendocrine differentiation in thymic epithelial tumors with special reference to thymic carcinoma and atypical thymoma. Hum. Pathol. 1998, 29: 330–338.PubMedCrossRefGoogle Scholar
  21. 21.
    Virgolini I., Leimer M., Handmarker H., Lastoria S., Nischof C., Muto P., Pangerl T., Gludovacz D., Peck-Radosavljevic M., Lister-James J., Hamilton G., Kaserer K., Valent P., Dean R. Somatostatin receptor subtype specificity and in vivo binding of a novel turmor tracer, 99mTc-P829. Cancer Res. 1998, 58: 1850–1859.PubMedGoogle Scholar
  22. 22.
    Smith-Jones P.M., Bischof C., Leimer M., Gludovacz D., Angelberger P., Pangerl T., Peck-Radosavljevic M., Hamilton G., Kaserer K., Kofler A., Valent P., Schlagbauer-Wadl H., Traub T., Virgolini I. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology 1999, 140: 5136–5148.PubMedGoogle Scholar
  23. 23.
    Krenning E.P., de Jong M., Kooij P.P., Breeman W.A., Bakker W.H., de Herder W.W., van Eijck C.H., Kwekkeboom D.J., Jamar F., Pauwels S., Valkema R. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann. Oncol. 1999, 10: S23–S29.PubMedCrossRefGoogle Scholar
  24. 24.
    Schally A.V., Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur. J. Endocrinol. 1999, 141: 1–14.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2001

Authors and Affiliations

  • Diego Ferone
    • 1
  • D. J. Kwekkeboom
    • 2
  • R. Pivonello
    • 1
  • A. D. J. J. Bogers
    • 3
  • A. Colao
    • 5
  • S. W. J. Lamberts
    • 1
  • P. M. van Hagen
    • 4
  • L. J. Hofland
    • 1
  1. 1.Department of Internal MedicineErasmus Medical Center Rotterdam (EMCR)The Netherlands
  2. 2.Department of Nuclear MedicineErasmus Medical Center Rotterdam (EMCR)The Netherlands
  3. 3.Department of SurgeryErasmus Medical Center Rotterdam (EMCR)The Netherlands
  4. 4.Department of ImmunologyErasmus Medical Center Rotterdam (EMCR)The Netherlands
  5. 5.Department of Molecular and Clinical Endocrinology and Oncology“Federico II” UniversityNaplesItaly

Personalised recommendations